Yeni Kardiyovasküler İlaçların Gebe Hastalarda Kullanımı: Teratojenik Riskler

Yeni oral antikoagülan ilaçlar dabigatran, rivaroksaban, apiksaban, edoksaban; antitrombositer ajanlar prasugrel, tikagrelor; antilipidemik ajanlar alirocumab ve evolocumab kardiyovasküler tedavilere alternatif yeni ajanlar olarak geliştirilmiş olup günümüzde sıklıkla reçetelendirilmektedir. Bu ajanlara maruz kalacak olan gebe hastaların veya gebeliğinin farkında olmadan ilacı kullanan kadınların sayısının yakın gelecekte hızla artması muhtemeldir. Bu çalışmada, farmakokinetik parametrelerin ışığı altında bu ilaçların gebelikte maruziyeti ile ilgili literatürdeki hayvan çalışmaları ve insan gebelik raporları incelenmiş ve bu ilaçların gebelikte kullanımı sonucunda oluşabilecek potansiyel teratojenik etkiler derlenmiştir.

Use of Novel Cardiovascular Drugs in Pregnant Patients: Teratogenic Risks

New oral anticoagulant drugs dabigatran, rivaroxaban, apixaban, edoxaban; antithrombotic agents prasugrel, ticagrelor; antilipidemic agents alirocumab and evolocumab have been developed as alternative agents to cardiovascular treatments and are frequently prescribed. It is likely that the number of pregnant patients who will be exposed to these agents or the number of women who are unaware of their pregnancy will increase rapidly in the near future. In this study, under the light of pharmacokinetic parameters, animal studies and human pregnancy reports in the literature about exposure to these new drugs during pregnancy were reviewed and the potential teratogenic effects of these drugs were summarized.

PDF

___

McDonagh M, Peterson K, Holzhammer B, Fazio S. A systematic review of PCSK9 inhibitors alirocumab and evolocumab. J Manag Care Spec Pharm. 2016;22:641-53.
Zhang H, Zhang P, Dong P, Yang X, Wang Y, Zhang H et al. Effect of ticagrelor versus prasugrel on platelet reactivity: a meta-analysis. Coron Artery Dis. 2017;28:597-604.
Yang J, Zeng P, Cai WY. Comparison of treatment outcomes of ticagrelor and clopidogrel among patients undergoing percutaneous coronary intervention: a meta-analysis. J Huazhong Univ Sci Technolog Med Sci. 2017;37:675-80.
Hoeltzenbein M, Beck E, Meixner K, Schaefer C, Kreutz R. Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre. Clin Res Cardiol. 2016;105:117- 26.
Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in Pregnancy and Lactation, 11th ed. Alphen aan den Rijn, The Netherlands. 2017.
Boehringer Ingelheim Pharmaceuticals. Product information: Pradaxa. Ridgefield, CT, Boehringer Ingelheim Pharmaceuticals, 2018.
U.S.FDA.2010. Dabigatran summary review. Erişim tarihi: 05.02.2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022512Orig1s000SumR.pdf
Huisman MV. Further issues with new oral anticoagulants. Curr Pharm Des. 2010;16:3487-9.
Bapat P, Kedar R, Lubetsky A, Matlow JN, Aleksa K, Berger H. et al. Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. Obstet Gynecol 2014;123:1256-61.
Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ. American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):7-47.
Cutts BA, Dasgupta D, Hunt BJ. New directions in the diagnosis and treatment of pulmonary embolism in pregnancy. Am J Obstet Gynecol 2013;208:102-8.
Reprotox. Available from http://www.micromedexsolutions.com. Accessed at 11.12.2017.
Janssen Pharmaceuticals Product information: Xarelto. Titusville, NJ, Janssen Pharmaceuticals, 2011.
Huisman MV. Further issues with new oral anticoagulants. Curr Pharm Des. 2010;16:3487–9.
Bapat P, Pinto LS, Lubetsky A, Berger H, Koren G. Rivaroxaban transfer across the dually perfused isolated human placental cotyledon. Am J Obstet Gynecol. 2015;213:710.e1–6
Bayer. Product information: Xarelto 20 mg film-coated tablets. Leverkusen, Bayer, 2017.
Cutts BA, Dasgupta D, Hunt BJ. New directions in the diagnosis and treatment of pulmonary embolism in pregnancy. Am J Obstet Gynecol. 2013;208:102-8.
Myers B, Neal R, Myers O, Ruparelia M. Unplanned pregnancy on a direct oral anticoagulant (rivaroxaban): A warning. Obstet Med. 2015;9:40-2.
Konigsbrugge O, Langer M, Hayde M, Ay C, Pabinger I. Oral anticoagulation with rivaroxaban during pregnancy: a case report. Thromb Haemost 2014;112:1323-4.
Uptodate. Dabigatran: drug information. Available from: https://www.uptodate.com/contents/ dabigatran-drug-information? source=search_result&search=dabigatran &selectedTitle= 1~132#references. Accessed at 13.12.2017.
Bristol-Myers Squibb, Product information. Eliquis. New York, Bristol-Myers Squibb, 2012.
Wang L, He K, Maxwell B, Grossman SJ, Tremaine LM, Humphreys WG, et al. Tissue distribution and elimination of [14C]apixaban in rats. Drug Metab Dispos. 2011;39:256-64.
Bapat P, Pinto LSR, Lubetsky A, Aleska K, Berger H, Koren G, et al. Examining the transplacental passage of apixaban using the dually perfused human placenta. J Thromb Haemost. 2016;14:1436–41.
Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e691S-736S.
Daiichi Sankyo. Product information: Savaysa. Tokyo, Japan, Daiichi Sankyo, 2015.
Uptodate. Edoxaban: drug information. Available from: https://www.uptodate.com/contents/edoxaban-drug-information? Source = search_result &search=edoxaban&selectedTitle=1~67. Accessed at 17.12.2017.
Lilly. Product information: Effient. Indianapolis, IndianaEli Lilly, 2009.
Daiichi Sankyo. Product information: Effient. Tokyo, Japan, Daiichi Sankyo, 2009.
Tello-Montoliu A, Seecheran NA, Angiolillo DJ. Successful pregnancy and delivery on prasugrel treatment: considerations for the use of dual antiplatelet therapy during pregnancy in clinical practice. J Thromb Thrombolysis 2013;36:348-51.
Astra Zeneca. Product information: Brilinta. Cambridge, UK, AstraZeneca, 2011.
Uptodate. Ticagrelor: drug information. Available from: https://www.uptodate.com/ contents/ticagrelor-drug-information?source=search_result& search= ticagrelor &selectedTitle=1~69. Accessed at 05.12.2017.
Sanofi Aventis. Product information: Praluent. Paris, France, Sanofi-Aventis, 2015.
Uptodate. Alirocumab: drug information. Available from: https://www.uptodate.com/contents/ alirocumab-drug-information?source=preview&search= alirocumab&anchor= F28895637# F28895637. Accessed at 17.12.2017.
Amgen. Product information. Repatha. Thousand Oaks, Ca, Amgen, 2016.
Uptodate. Evolocumab: drug information. Available from: https://www.uptodate.com/contents/evolocumab-drug-information?source=preview& search= evolocumab& anchor=F29871556#F29871556. Accessed at 17.12.2017.